| ID | 10208 |
| Vaccine Name | cAd3 Marburg (VRC-MARADC087-00-VP) |
| Disease Name | Marburg hemorrhagic fever |
| Disease Classification | Hemorrhagic |
| Virus Name | Marburg virus |
| Nucleic Acid Content | negative-sense, single-stranded RNA |
| Vaccine Type | Recombinant viral vector |
| Vaccine Status | Phase 1 |
| Manufacturer | National Institute of Allergy and Infectious Diseases |
| Year of Manufacturing | 2021 |
| Manufacturing Country | USA |
| Age | 18 - 50 years |
| Dosage | Single dose |
| Administration Route | Intramuscular |
| Adjuvant | NA |
| Target Strain | Marburg wild type glycoprotein |
| Description | NA |
| Approving Organisation | US FDA |
| Collaborating Organisation | US Military HIV Research Program |
| Other Countries | NA |
| Trade Name | NA |
| PMID | NA |
| Clinical Trial ID | NCT03475056 |
| Reference Link | https://clinicaltrials.gov/ct2/show/NCT03475056?cond=Marburg+hemorrhagic+fever&draw=2&rank=3 |
| Additional Links | NA
|